Mature latin businessman showing stock market bar graph to businesswoman. Financial advising team discussing trading patterns of year. Rear view of casual businesspeople holding charts studying year trend together.

TherapeuticsMD, Inc.[TXMD] stock saw a move by 1.28% on , touching 2.04 million. Based on the recent volume, TherapeuticsMD, Inc. stock traders appear to be active. The most recent trading volume of TXMD shares recorded 266.54M shares, which represents the daily volume of traded shares. Analysts estimates state that TherapeuticsMD, Inc. [TXMD] stock could reach median target price of $7.00.

TherapeuticsMD, Inc. [TXMD] stock additionally went up by +1.28% in the period of the 7 days, recording a N/A in performance by 0.00% in the last 30 days. The yearly more of TXMD stock is set at -53.98% by far, with shares price recording returns by -38.36% in the latest quarter. Over the past six months, TXMD shares showcased -4.44% decrease. TXMD saw -61.08% change opposing the low price in the last 12 months, also recording 30.22% compared to high within the same period of time.

TherapeuticsMD, Inc. [NASDAQ:TXMD]: Analyst Rating and Earnings

Its stock price has been found in the range of 1.82 to 6.09. This is compared to its latest closing price of $2.34.

Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Thu 20 Feb (In 38 Days).

Fundamental Analysis of TherapeuticsMD, Inc. [TXMD]

Now let’s turn to look at profitability: with a current Operating Margin for TherapeuticsMD, Inc. [TXMD] sitting at -808.85 and its Gross Margin at +81.17.

This company’s Return on Total Capital is -86.58, and its Return on Invested Capital has reached -76.20%. Its Return on Equity is -116.62, and its Return on Assets is -74.67. These metrics suggest that this TherapeuticsMD, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, TherapeuticsMD, Inc. [TXMD] has generated a Total Debt to Total Equity ratio of 75.24. Similarly, its Total Debt to Total Capital is 42.94, while its Total Debt to Total Assets stands at 34.62. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -27.84, and its Long-Term Debt to Total Capital is 75.24.

What about valuation? This company’s Enterprise Value to EBITDA is -4.14. The Enterprise Value to Sales for this firm is now 13.86, and its Total Debt to Enterprise Value stands at 0.10. TherapeuticsMD, Inc. [TXMD] has a Price to Book Ratio of 9.39.

Shifting the focus to workforce efficiency, TherapeuticsMD, Inc. [TXMD] earns $66,803 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 2.09 and its Total Asset Turnover is 0.09. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 4.42 and its Current Ratio is 4.50. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

TherapeuticsMD, Inc. [TXMD] has 266.54M shares outstanding, amounting to a total market cap of $631.70M. Its stock price has been found in the range of 1.82 to 6.09. At its current price, it has moved down by -61.08% from its 52-week high, and it has moved up 30.22% from its 52-week low.

This stock’s Beta value is currently 1.62, which indicates that it is 4.89% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 47.12. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is TherapeuticsMD, Inc. [TXMD] a Reliable Buy?

Shares of TherapeuticsMD, Inc. [TXMD], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.